SQI Diagnostics 将来の成長

Future 基準チェック /06

現在、 SQI Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、SQI Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

TSXV:SQD.H - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2023	3	-19	0	-6	N/A
12/31/2022	8	-18	-9	-8	N/A
9/30/2022	8	-19	-11	-10	N/A
6/30/2022	7	-13	-17	-9	N/A
3/31/2022	6	-9	-19	-10	N/A
12/31/2021	1	-10	-13	-11	N/A
9/30/2021	1	-11	-10	-9	N/A
6/30/2021	1	-11	-10	-9	N/A
3/31/2021	1	-12	-8	-8	N/A
12/31/2020	1	-10	-7	-6	N/A
9/30/2020	1	-9	-7	-7	N/A
6/30/2020	1	-9	-8	-7	N/A
3/31/2020	2	-9	-7	-7	N/A
12/31/2019	2	-8	-6	-6	N/A
9/30/2019	2	-8	-6	-6	N/A
6/30/2019	2	-7	-5	-5	N/A
3/31/2019	1	-7	-6	-6	N/A
12/31/2018	1	-7	-7	-6	N/A
9/30/2018	1	-7	-7	-7	N/A
6/30/2018	1	-7	-6	-6	N/A
3/31/2018	1	-7	-6	-6	N/A
12/31/2017	1	-6	-6	-6	N/A
9/30/2017	1	-6	-5	-5	N/A
6/30/2017	2	-6	-5	-5	N/A
3/31/2017	2	-5	-5	-5	N/A
12/31/2016	2	-5	N/A	-4	N/A
9/30/2016	1	-5	N/A	-5	N/A
6/30/2016	1	-5	N/A	-5	N/A
3/31/2016	1	-5	N/A	-5	N/A
12/31/2015	1	-6	N/A	-5	N/A
9/30/2015	0	-6	N/A	-5	N/A
6/30/2015	0	-6	N/A	-5	N/A
3/31/2015	0	-6	N/A	-5	N/A
12/31/2014	0	-5	N/A	-5	N/A
9/30/2014	0	-5	N/A	-5	N/A
6/30/2014	0	-5	N/A	-5	N/A
3/31/2014	0	-6	N/A	-4	N/A
12/31/2013	0	-6	N/A	-5	N/A
9/30/2013	0	-6	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SQD.Hの予測収益成長が貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: SQD.Hの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: SQD.Hの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: SQD.Hの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SQD.Hの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SQD.Hの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

SQI Diagnostics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘